Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PCI Biotech Holding ASA ( (DE:4QG) ) just unveiled an update.
PCI Biotech Holding ASA has concluded its review of strategic alternatives following the earlier decision to discontinue all research and development activities, and the board has now resolved to initiate a process to evaluate a structured wind-up of the company. The group’s liquidity position remains critical, casting serious doubt on its ability to continue as a going concern and leaving uncertainty as to whether a wind-up process can be successfully completed, signaling a potentially terminal phase for the business and heightened risk for shareholders and other stakeholders.
More about PCI Biotech Holding ASA
PCI Biotech Holding ASA is a Norwegian biotechnology company listed on the Oslo Stock Exchange that has been focused on research and development activities, leveraging its proprietary technologies within the life sciences sector.
Average Trading Volume: 133,542
Current Market Cap: NOK10.04M
See more data about 4QG stock on TipRanks’ Stock Analysis page.